Prostate specific antigen following radiotherapy for local prostate cancer.
The clinical recurrence-free survival rates were compared to the combined clinical and biochemical recurrence-free survival rates in 285 patients with stages A2 (T1b), B (T2) and C (T3) prostate cancer treated with radiation therapy. For stages A2 (T1b) and B (T2) disease the 10-year clinical recurrence-free survival rate was 48% and the corresponding 10-year clinical and biochemical recurrence-free survival rate was 33%. For stage C (T3) disease these rates were 33% and 22%, respectively. These results demonstrate that approximately a third of the patients who are considered recurrence-free by standard clinical criteria at 10 years after radiation therapy have elevated prostate specific antigen values and are at significant risk for later clinical failure.
Rosenzweig
K E
KE
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Morgan
W R
WR
Lytton
B
B
Peschel
R E
RE
D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000097:blood* / Q000401:mortality / Q000532:radiotherapy*; D000368:Aged; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen